20240033306. Microbiome-based informed method to formulate live biotherapeutics simplified abstract (University of Maryland, Baltimore)
Contents
Microbiome-based informed method to formulate live biotherapeutics
Organization Name
University of Maryland, Baltimore
Inventor(s)
Jacques Ravel of Laurel MD (US)
Michael France of Baltimore MD (US)
Lindsay Rutt of Baltimore MD (US)
Microbiome-based informed method to formulate live biotherapeutics - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240033306 titled 'Microbiome-based informed method to formulate live biotherapeutics
Simplified Explanation
The patent application discloses methods for formulating live biotherapeutics to address deficiencies or excesses of specific bacterial strains in a person's microbiome. This is achieved by comparing a gene-specific characterization of the person's microbiome against a comprehensive reference gene catalog. The biotherapeutic is then formulated by selecting bacteria to address the identified deficiency or excess.
- The patent application focuses on formulating live biotherapeutics to improve the health of a person's vaginal microbiome.
- The formulation process involves using a vaginal reference gene catalog to identify and select bacteria to address any deficiencies or excesses in the microbiome.
- The technology may be applicable for ameliorating, treating, or preventing malignancies such as cancers of the female genitourinary system.
Potential Applications:
- Improving the health of a person's vaginal microbiome.
- Treating or preventing malignancies of the female genitourinary system.
Problems Solved:
- Addressing deficiencies or excesses of specific bacterial strains in a person's microbiome.
- Improving the balance and overall health of the vaginal microbiome.
Benefits:
- Personalized approach to formulating live biotherapeutics based on individual microbiome characteristics.
- Potential for targeted treatment and prevention of specific health conditions related to the microbiome.
- Improved understanding and management of vaginal microbiome health.
Original Abstract Submitted
methods of formulating live biotherapeutics are disclosed in which a deficiency or excess of a specific bacterial strain in a person's microbiome is identified by comparing a gene-specific characterization of the person's microbiome against a comprehensive, non-redundant reference gene catalog, and the biotherapeutic is formulated by selecting bacteria to address the deficiency or excess. embodiments include the formulation of live biotherapeutics for improving the health of a person's vaginal microbiome, i.e. using a vaginal reference gene catalog, and may be suitable for ameliorating, treating, or preventing a malignancy such as a cancer of the female genitourinary system.
